CCR5 in cancer immunotherapy: More than an "attractive" receptor for T cells

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 106-108

  González Martín, Alicia ^a,b   Mira, Emilia ^a   Mañes, Santos ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Activation; Antigen presenting cell; Cancer; CCR5; CD4 help; Chemokines; Cross priming; Immunotherapy; Maturation; T cell; TLR

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RANTES;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MOLECULAR DYNAMICS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; THERAPY EFFECT; UPREGULATION;

EID: 84872660433     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.17995     Document Type: Note

References (10)

1. Viola A, Contento RL, Molon B. T cells and their partners: The chemokine dating agency. Trends Immunol 2006; 27:421-7; DOI:10.1016/j.it.2006.07.004.
2. Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther 2010; 10:725-33; DOI:10.1517/14712591003657128.
3. Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 2010; 70:490-500; DOI:10.1158/0008-5472.CAN-09-1890.
4. + T cells. Cancer Res 2011; 71:5455-66; DOI:10.1158/0008-5472.CAN-11-1687.
5. Molon B, Gri G, Bettella M, Gómez-Moutón C, Lanzavecchia A, Martinez AC, et al. T cell costimulation by chemokine receptors. Nat Immunol 2005; 6:465-71; DOI:10.1038/ni1191.
6. + T cells elicit host immune responses to MHC class II-ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol 2010; 184:5654-62; DOI:10.4049/jimmunol.0903247.
7. + T cell-dendritic cell interaction. Nature 2006; 440:890-5; DOI:10.1038/nature04651.
8. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29:372-83; DOI:10.1016/j.immuni.2008.08.004.
9. + T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol 2004; 34:752-61; DOI:10.1002/eji.200324427.
10. Crawford A, Angelosanto JM, Nadwodny KL, Blackburn SD, Wherry EJ. A role for the chemokine RANTES in regulating CD8 T Cell responses during chronic viral infection. PLoS Pathog 2011; 7:1002098; DOI:10.1371/journal.ppat.1002098.